Latest Kane Biotech (KNBIF) Headlines
Kane Biotech Receives $397,500 From Warrant Exercise
Marketwire - Tue Feb 04, 7:05AM CST
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, is pleased to announce it has received a total of $397,500 from the exercising of 2,650,000 warrants at $.15 per share from warrant holders. The warrants were issued on December 14, 2012 as part of a previously announced financing.
Global Medical Device Coatings Market 2012-2016 with Hydromer Inc., Materion Corp., Surmodics Inc., and Sono-Tek Corp. Dominating
M2 - Tue Jan 21, 9:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/mvs7l6/global_medical) has announced the addition of the "Global Medical Device Coatings Market 2012-2016" report to their offering. The analysts forecast the Global Medical Device Coatings market to grow at a CAGR of 8.55 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increased awareness of minimally invasive surgeries. The Global Medical Device Coatings Market has also been witnessing an increased use of super hydrophilic coating in medical devices. However, the regulation for medical devices varies across countries and could pose a challenge to the growth of this market. The key vendors dominating this space include Hydromer Inc., Materion Corp., Surmodics Inc., and Sono-Tek Corp. The other vendors mentioned in the report are Abbott Laboratories, Angiotech Pharmaceuticals Inc., Bayer Material Science LLC, Biocoat Inc., Boston Scientific Corp., Carmeda AB, Cook Medical Inc., Cordis Corp., Covalon Technologies Ltd., Covidien Plc, CR Bard, DePuy Inc., EIS Optics Ltd., Endura Coatings Ltd., Ionbond AG, Jotec GmbH, Kane Biotech Inc., Medi-Solve Coatings LLC, Medtronic Inc., N8 Medical Inc, Parker Medical Systems, Parlex Corp., Precision Coating Company Inc., Royal DSM N.V., Specialty Coating Systems Inc., Spectranectics Corp., Stryker Corp., and TheraSyn Pharmaceuticals Inc. Commenting on the report, an analyst from the Healthcare team said: Medical devices that require excellent water attraction and optical clarity have super-hydrophilic coatings. Super-hydrophilic coatings are increasingly being preferred by medical device manufacturers for use on their products because these coatings have several advantages. This type of coating is used on catheters that require lubrication when inserted in percutaneous trans-luminal coronary angioplasty surgery and for stent placement. Hence, the growing popularity of super-hydrophilic coatings is a new trend that is expected to have a strong impact on the market. For more information visit http://www.researchandmarkets.com/research/mv...al_medical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
DispersinB(R) Topical Spray Approval from Health Canada's LRVHP Program
Marketwire - Tue Jan 07, 7:03AM CST
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, is pleased to announce it has received Notification Number "NN.XZ5M" from the Interim Notification Program for Low Risk Veterinary Health Products (LRVHP) for the Company's first dermatological formulation (under the brand name DispersinB). DispersinB Topical Spray is a unique antibiofilm-antimicrobial and non-antibiotic formulation that can be applied to the skin and coat of dogs and horses.
Kane Biotech Announces Closing of Private Placement Offering
Marketwire - Wed Dec 18, 4:57PM CST
Kane Biotech Inc. (TSX VENTURE: KNE) (the "Corporation") today announced that the Corporation has closed its previously announced non-brokered private placement offering (the "Offering") of a single unit (the "Unit") comprised of a $500,000 principal amount 2 year 10% convertible redeemable unsecured note (the "Note") and 4,000,000 share purchase warrants ("Warrants") for gross proceeds of $500,000.
Kane Biotech Signs Option Agreement With Global Health Care Company
Marketwire - Tue Dec 17, 7:02AM CST
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, today announces the Company has entered into an option agreement with a Global Health Care Company who has been assessing some of Kane Biotech's antibiofilm and antimicrobial technologies for use in the animal heath market.
Kane Biotech Announces Extension of Warrants and Private Placement Offering
Marketwire - Fri Dec 06, 7:01AM CST
Kane Biotech Inc. (TSX VENTURE: KNE) (the "Corporation") today announced that it has amended the terms of its 18,035,000 share purchase warrants (the "December 2012 Warrants") issued on December 14, 2012 by extending the expiry thereof from December 14, 2013 to January 31, 2014. The TSX Venture Exchange has granted its approval for the extension to the term of the December 2012 Warrants. The Corporation will send a notice to all holders of December 2012 Warrants notifying them of the extension to the term of the December 2012 Warrants.
Global Medical Antimicrobial Coatings Market 2012-2016: Estimations Reveal that Every Year 1.7 Million Cases of Hospital Acquired Infections Occur in the US
M2 - Wed Nov 27, 11:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/877k58/global_medical) has announced the addition of the "Global Medical Antimicrobial Coatings Market 2012-2016" report to their offering. The analysts forecast the Global Medical Antimicrobial Coatings market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of hospital-acquired infection. The Global Medical Antimicrobial Coatings market has also been witnessing increasing partnership activities among vendors. However, the stringent regulation policies could pose a challenge to the growth of this market. The key vendors dominating this market space are BASF SE, Covalon Technologies Ltd., Hydromer Inc., Royal DSM N.V, and Sono-Tek Corp. Other vendors mentioned in the report are Biocoat Inc., Kane Biotech Inc., Nanexa AB, Specialty Coating Systems Inc., and TheraSyn Pharmaceuticals Inc. Commenting on the report, an analyst from the team said: Owing to the growing potential of the Global Medical Device market, many medical device manufacturers collaborate to develop high-quality antimicrobial-based medical devices. For example, BASF Future Business GmbH, a subsidiary of BASF SE, announced collaboration with Medi-Solve Coatings LLC for antimicrobial coatings of catheters and other minimally invasive medical devices. This collaboration combines Medi-Solve's proprietary AquaCoat coating technology with BASF Future Business' proprietary HyGentic silver-based antimicrobial additive platform. Similarly, Hydromer Inc. signed two licensing agreements for its coating technology, one with a US-based medical device company and another with a Chinese medical device company. Thus, the increase in partnership activities is expected to drive the growth of the Global Medical Antimicrobial Coatings market. For more information visit http://www.researchandmarkets.com/research/87...al_medical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
New StrixNB(TM) Pet Oral Care Approval from Heath Canada's LRVHP Program
Marketwire - Wed Nov 06, 7:02AM CST
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce it has received Notification Number "NN.TZMT" from the Interim Notification Program for Low Risk Veterinary Health Products (LRVHP) for a new StrixNB oral care product in Canada. With the issuance of this notification number, the Company has cleared the final requirements for StrixNB Oral Care Spray to enter the companion animal market in Canada.
Kane Biotech Announces Board Members
Marketwire - Thu Jun 06, 11:29AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce that the Company's Annual and Special Meeting of shareholders held on June 5, 2013 (the "Meeting"), the following individuals have been elected to the board of directors; Philip Renaud (Chairman), Dr. Arvind Joshi, Gordon Froehlich and Richard Cherney. All four individuals were current members of the board of directors of Kane Biotech Inc. and had let their names stand for re-election at the Meeting.
BC Pet Owners Have a New Weapon Against Dog Breath
Marketwire - Wed May 22, 6:01AM CDT
A brand new, Canadian-made invention is officially in British Columbia now to help improve companion animals' oral hygiene and prevent bad breath. Kane Biotech Inc. (TSX VENTURE: KNE) is pleased to mark the official introduction of its StrixNB pet oral care product to the BC market today at Market Hill Animal Hospital in Vancouver.
StrixNB(TM) Significantly Reduces Bad Breath in Dogs
Marketwire - Thu Apr 04, 7:02AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE), is pleased to report that in a recently completed dog efficacy field study, StrixNB was very effective against halitosis (bad breath). The study was conducted on Sheltie dogs. Kane Biotech is a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms.
Kane Biotech Receives $397,500 From Warrant Exercise
Marketwire - Tue Feb 04, 7:05AM CST
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, is pleased to announce it has received a total of $397,500 from the exercising of 2,650,000 warrants at $.15 per share from warrant holders. The warrants were issued on December 14, 2012 as part of a previously announced financing.
Global Medical Device Coatings Market 2012-2016 with Hydromer Inc., Materion Corp., Surmodics Inc., and Sono-Tek Corp. Dominating
M2 - Tue Jan 21, 9:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/mvs7l6/global_medical) has announced the addition of the "Global Medical Device Coatings Market 2012-2016" report to their offering. The analysts forecast the Global Medical Device Coatings market to grow at a CAGR of 8.55 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increased awareness of minimally invasive surgeries. The Global Medical Device Coatings Market has also been witnessing an increased use of super hydrophilic coating in medical devices. However, the regulation for medical devices varies across countries and could pose a challenge to the growth of this market. The key vendors dominating this space include Hydromer Inc., Materion Corp., Surmodics Inc., and Sono-Tek Corp. The other vendors mentioned in the report are Abbott Laboratories, Angiotech Pharmaceuticals Inc., Bayer Material Science LLC, Biocoat Inc., Boston Scientific Corp., Carmeda AB, Cook Medical Inc., Cordis Corp., Covalon Technologies Ltd., Covidien Plc, CR Bard, DePuy Inc., EIS Optics Ltd., Endura Coatings Ltd., Ionbond AG, Jotec GmbH, Kane Biotech Inc., Medi-Solve Coatings LLC, Medtronic Inc., N8 Medical Inc, Parker Medical Systems, Parlex Corp., Precision Coating Company Inc., Royal DSM N.V., Specialty Coating Systems Inc., Spectranectics Corp., Stryker Corp., and TheraSyn Pharmaceuticals Inc. Commenting on the report, an analyst from the Healthcare team said: Medical devices that require excellent water attraction and optical clarity have super-hydrophilic coatings. Super-hydrophilic coatings are increasingly being preferred by medical device manufacturers for use on their products because these coatings have several advantages. This type of coating is used on catheters that require lubrication when inserted in percutaneous trans-luminal coronary angioplasty surgery and for stent placement. Hence, the growing popularity of super-hydrophilic coatings is a new trend that is expected to have a strong impact on the market. For more information visit http://www.researchandmarkets.com/research/mv...al_medical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
DispersinB(R) Topical Spray Approval from Health Canada's LRVHP Program
Marketwire - Tue Jan 07, 7:03AM CST
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, is pleased to announce it has received Notification Number "NN.XZ5M" from the Interim Notification Program for Low Risk Veterinary Health Products (LRVHP) for the Company's first dermatological formulation (under the brand name DispersinB). DispersinB Topical Spray is a unique antibiofilm-antimicrobial and non-antibiotic formulation that can be applied to the skin and coat of dogs and horses.
Kane Biotech Announces Closing of Private Placement Offering
Marketwire - Wed Dec 18, 4:57PM CST
Kane Biotech Inc. (TSX VENTURE: KNE) (the "Corporation") today announced that the Corporation has closed its previously announced non-brokered private placement offering (the "Offering") of a single unit (the "Unit") comprised of a $500,000 principal amount 2 year 10% convertible redeemable unsecured note (the "Note") and 4,000,000 share purchase warrants ("Warrants") for gross proceeds of $500,000.
Kane Biotech Signs Option Agreement With Global Health Care Company
Marketwire - Tue Dec 17, 7:02AM CST
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, today announces the Company has entered into an option agreement with a Global Health Care Company who has been assessing some of Kane Biotech's antibiofilm and antimicrobial technologies for use in the animal heath market.
Kane Biotech Announces Extension of Warrants and Private Placement Offering
Marketwire - Fri Dec 06, 7:01AM CST
Kane Biotech Inc. (TSX VENTURE: KNE) (the "Corporation") today announced that it has amended the terms of its 18,035,000 share purchase warrants (the "December 2012 Warrants") issued on December 14, 2012 by extending the expiry thereof from December 14, 2013 to January 31, 2014. The TSX Venture Exchange has granted its approval for the extension to the term of the December 2012 Warrants. The Corporation will send a notice to all holders of December 2012 Warrants notifying them of the extension to the term of the December 2012 Warrants.
Global Medical Antimicrobial Coatings Market 2012-2016: Estimations Reveal that Every Year 1.7 Million Cases of Hospital Acquired Infections Occur in the US
M2 - Wed Nov 27, 11:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/877k58/global_medical) has announced the addition of the "Global Medical Antimicrobial Coatings Market 2012-2016" report to their offering. The analysts forecast the Global Medical Antimicrobial Coatings market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of hospital-acquired infection. The Global Medical Antimicrobial Coatings market has also been witnessing increasing partnership activities among vendors. However, the stringent regulation policies could pose a challenge to the growth of this market. The key vendors dominating this market space are BASF SE, Covalon Technologies Ltd., Hydromer Inc., Royal DSM N.V, and Sono-Tek Corp. Other vendors mentioned in the report are Biocoat Inc., Kane Biotech Inc., Nanexa AB, Specialty Coating Systems Inc., and TheraSyn Pharmaceuticals Inc. Commenting on the report, an analyst from the team said: Owing to the growing potential of the Global Medical Device market, many medical device manufacturers collaborate to develop high-quality antimicrobial-based medical devices. For example, BASF Future Business GmbH, a subsidiary of BASF SE, announced collaboration with Medi-Solve Coatings LLC for antimicrobial coatings of catheters and other minimally invasive medical devices. This collaboration combines Medi-Solve's proprietary AquaCoat coating technology with BASF Future Business' proprietary HyGentic silver-based antimicrobial additive platform. Similarly, Hydromer Inc. signed two licensing agreements for its coating technology, one with a US-based medical device company and another with a Chinese medical device company. Thus, the increase in partnership activities is expected to drive the growth of the Global Medical Antimicrobial Coatings market. For more information visit http://www.researchandmarkets.com/research/87...al_medical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
New StrixNB(TM) Pet Oral Care Approval from Heath Canada's LRVHP Program
Marketwire - Wed Nov 06, 7:02AM CST
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce it has received Notification Number "NN.TZMT" from the Interim Notification Program for Low Risk Veterinary Health Products (LRVHP) for a new StrixNB oral care product in Canada. With the issuance of this notification number, the Company has cleared the final requirements for StrixNB Oral Care Spray to enter the companion animal market in Canada.
Kane Biotech Announces Board Members
Marketwire - Thu Jun 06, 11:29AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce that the Company's Annual and Special Meeting of shareholders held on June 5, 2013 (the "Meeting"), the following individuals have been elected to the board of directors; Philip Renaud (Chairman), Dr. Arvind Joshi, Gordon Froehlich and Richard Cherney. All four individuals were current members of the board of directors of Kane Biotech Inc. and had let their names stand for re-election at the Meeting.
BC Pet Owners Have a New Weapon Against Dog Breath
Marketwire - Wed May 22, 6:01AM CDT
A brand new, Canadian-made invention is officially in British Columbia now to help improve companion animals' oral hygiene and prevent bad breath. Kane Biotech Inc. (TSX VENTURE: KNE) is pleased to mark the official introduction of its StrixNB pet oral care product to the BC market today at Market Hill Animal Hospital in Vancouver.
StrixNB(TM) Significantly Reduces Bad Breath in Dogs
Marketwire - Thu Apr 04, 7:02AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE), is pleased to report that in a recently completed dog efficacy field study, StrixNB was very effective against halitosis (bad breath). The study was conducted on Sheltie dogs. Kane Biotech is a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms.
